Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 105 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Spironolactone (drug) Clear all
Not listed Early Phase 1 Interventional

The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

NCT05995392
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Topical spironolactone ophthalmic solution, 0.005 mg/cc, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 4, 2026, 9:24 PM EDT
Not listed Not applicable Interventional

Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

NCT01422759
View directory record Official record
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Spironolactone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men

NCT01294319
View directory record Official record
Conditions
Cortisol Resistance, Negative Feedback, ACTH, Mineralcorticoid, Glucocorticoid
Interventions
Mifepristone, Placebo, Spironolactone, Combined, Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Not applicable Interventional

Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study

NCT02167464
View directory record Official record
Conditions
Hypertension
Interventions
Renin treatment-guided Therapeutics, Referral Hypertension specialist, Aldosterone Antagonist
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Anderson, South Carolina • Beaufort, South Carolina • Florence, South Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 4, 2026, 9:24 PM EDT
Withdrawn Phase 4 Interventional

Spironolactone Safety in Dialysis Patients

NCT00328809
View directory record Official record
Conditions
End Stage Renal Disease, Congestive Heart Failure
Interventions
spironolactone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 4, 2026, 9:24 PM EDT
Recruiting Not applicable Interventional

Arterial Stiffness and Blood Pressure

NCT06495710
View directory record Official record
Conditions
Hypertension, Vascular Stiffness, Aging
Interventions
Blood pressure treatment algorithm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hypoglycemia and Autonomic Nervous System Function-B

NCT03429946
View directory record Official record
Conditions
Hypoglycemia, Healthy
Interventions
Spironolactone, Placebo, Hypoglycemic Hyperinsulinemic Clamp, Euglycemic Hyperinsulinemic Clamp
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Not applicable Interventional Results available

Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease

NCT00865124
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Vascular Disease
Interventions
Spironolactone, Hydrochlorothiazide + potassium, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Biomarker Guided Therapies in Stage A/B Heart Failure

NCT02230891
View directory record Official record
Conditions
Hypertension, Diabetes, Cardiovascular Disease
Interventions
Carvedilol, Spironolactone, Usual care
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 4, 2026, 9:24 PM EDT
Not listed Phase 4 Interventional

Remission From Stage D Heart Failure

NCT01774656
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Pharmacological Treatment
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Louisville, Kentucky • Omaha, Nebraska • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 4 Interventional Results available

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

NCT00353652
View directory record Official record
Conditions
Hypertension
Interventions
Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 4, 2026, 9:24 PM EDT
Not listed Not applicable Interventional

Randomized Control Trial (RCT) of Early Palliative Care for HCC

NCT02556619
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Early Palliative Care/Symptom Control
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

NCT03048825
View directory record Official record
Conditions
ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
Interventions
Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo
Drug · Device
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
7,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 4, 2026, 9:24 PM EDT
Completed No phase listed Observational

Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas

NCT02362308
View directory record Official record
Conditions
Primary Aldosteronism
Interventions
Adrenalectomy, mineralocorticoid receptor antagonist
Other · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

NCT00094302
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
50 Years and older
Enrollment
3,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 4, 2026, 9:24 PM EDT
Recruiting Phase 1 Interventional

Spironolactone in Alcohol Use Disorder (SAUD)

NCT05807139
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Spironolactone
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Active, not recruiting Phase 4 Interventional

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

NCT07281014
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Spironolactone 25mg, Aldosterone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

NCT02585843
View directory record Official record
Conditions
Heart Failure
Interventions
Spironolactone 100mg, Spironolactone 25mg
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Spironolactone Therapy In Young Women With NASH

NCT03576755
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Spironolactone 100mg, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 4, 2026, 9:24 PM EDT
Withdrawn Phase 3 Interventional

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

NCT07223502
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Terminated Phase 4 Interventional Results available

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

NCT02253394
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan plus Spironolactone, Ambrisentan plus Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 4, 2026, 9:24 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 4, 2026, 9:24 PM EDT
Terminated Phase 1 Interventional Results available

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

NCT01488877
View directory record Official record
Conditions
Type 2 Diabetic Nephropathy
Interventions
PF-03882845, Spironolactone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Chula Vista, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 4, 2026, 9:24 PM EDT
Not listed Phase 2 Interventional

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

NCT05222191
View directory record Official record
Conditions
Renal Insufficiency, Chronic Hypertension
Interventions
Spironolactone, Chlorthalidone, Placebo
Drug
Lead sponsor
Indiana Institute for Medical Research
Other
Eligibility
19 Years to 110 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 4, 2026, 9:24 PM EDT